Association of Serum Magnesium Levels with Matrix metalloproteinase-9 (MMP-9) Urine in Patients with Diabetic Kidney Disease Stage 1 and 2
Downloads
Introduction: The progressiveness of stage 1 and 2 kidney disease is indicated by an increase in matrix metalloproteinase-9 (MMP-9). Development of diabetic kidney disease (DKD) is characterized by a thuckening of the glomerular basement membrane followed ultimately by progression to glomerular sclerosis and fibrosis. One of the factors that contribute is magnesium levels. This study aimed to determine the association between serum magnesium levels and MMP-9 urine in patients with stage 1 and 2 DKD.
Methods: This was a cross sectional study from stage 1 and 2 DKD patients. Patients were examined for serum magnesium levels and urine MMP-9. Urine MMP-9 examination was taken from the middle portion urine collection and examined using Sandwich-ELISA method then normalized with urine creatinine. The correlation between magnesium and MMP-9 urine was analyzed by the Spearman rank test.
Results: This study involved 56 subjects. The mean serum magnesium level was 1.8 ± 0.26 mg/dL. The mean MMP-9 was 120 ng/g creatinin. The mean value of FBG (fasting blood glucose) in patients in the study was 153.29±50.22 mg/dL. The mean value of PPG (post prandial glucose) was 233.61±71.3 mg/dL. The mean HbA1c value was 7.6±1.13%. The mean creatinin serum value was 1.1±0.43 mg/dL. There was a significant negative relationship with a moderate correlation between serum magnesium levels and urine MMP-9 (p = 0.000, r -0.512).
Conclusion: There was a significant negative relationship between serum magnesium levels and urine MMP-9 in stage 1 and 2 DKD patients.
Diaz AG, Villasenor LP, Escatell FG, Sierra JA. Oxidative Stress in Diabetic Nephropathy with Early Chronic Kidney Disease. Journal of Diabetes Research. 2016; 1-2
Pham PC, Pham PM, Pham PA, Pham SV. Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clin Nephrol. 2005; 63(6): 429-36.
Pham PC, Pham PM, Pham PT, Pham SV. The link between lower serum magnesium and kidney function in patients with diabetes mellitus type 2 deserves a closer look. Clin Nephrol, 2009; 71(4):375-9.
Hans CP, Sialy R& Bansal DD. Magnesium deficiency and diabetes mellitus. Current Science, 2002; 83(12): 156-1462.
Hasegawa G, Nakano K, Kondo M, 2005. Role of TNF and IL"‘1 in the development of diabetic nephropathy. Nefrologia, 15: 1–4
Lim, 2014. Diabetic nephropathy – complications and treatment. International Journal of Nephrology and Renovascular Disease 7: 361–381
Cheng Z, Limbu M, Wang Z, Liu J, Liu L, Zhang X, 2017. MMP-2 and 9 in Chronic Kidney. Int. J. Mol. Sci.18: 776
Mahendran K, Sethupathy S, Perumal K, Inmozhi R, Santha K, 2015. Plasma and urinary matrix metalloproteinase-9 as a marker for detection of nephropathy in type 2 diabetic patients. International Journal of Medical Science and Public Health 4(10):1409-1412
Osterby R, Gall MA, Schmitz A, Nielsen FS, Nyberg G, Parving HH: Glomerular structure and function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:1064–70.
Steffes MW, Osterby R, Chavers B, Mauer SM: Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 1989;38:1077–81
Osterby R, Tapia J, Nyberg G, Tencer J, Willner J, Rippe B, Torffvit O. Renal structures in type 2 diabetic patients with elevated albumin excretion rate. APMIS 2001;109:751–61.
Osterby R, Hartmann A, Nyengaard JR, Bangstad HJ. Development of renal structural lesions in type 1 diabetic patients with microalbuminuria. Observations by light microscopy in 8-year follow-up biopsies. Virchows Arch 2002;440:94–101
Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145–54.
Lenz O, Elliot SJ, Stetler-Stevenson WG. Matrix metalloproteinases in renal development and disease. JASN 2000;11(3):574–81.
Tashiro K, Koyanagi I, Ohara I, Ito T, Saitoh A, Horikoshi S, Tomino Y, 2004. Levels of Urinary Matrix Metalloproteinase-9 (MMP-9) and Renal Injuries in Patients With Type 2 Diabetic Nephropathy. Journal of Clinical Laboratory Analysis 18:206–210
Azeem M, Iqbal A, Butt N, Randhawa FA, Malik U, 2017. Frequency of Type-2 diabetes mellitus in Nephropathic patients and comparison of mean magnesium levels in Nephropathic patients with and without Type-2 diabetes mellitus. Pak J Med Sci 33(5): 1254-1259
Bherwani S, Jibhkate SB, Saumva AS, Patel SK, Singh R, 2016. Hypomagnesemia: a modifiable risk factor of diabetic nephropathy. Hormone molecular Biology and clinical investigation 29(3):79-84.
Silva AP, Fragoso A, Silva C, Tavares N, Santos N, Martins H, 2014. Magnesium and Mortality in Patients with Diabetes and Early Chronic Kidney Disease. J Diabetes Metab, 5:3
Derosa G, Maffioli P, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Mereu R, Palumbo I, Randazzo S, Cicero A. 2009. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. Clin Invest Med 32 (2): E124-E132.
Shet N, Shetty S, Rao A, 2014. To Study Serum Mmp-9 Levels In Early Diabetic Nephropathy. International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 – 6718
Copyright (c) 2019 M. Hashemi Rafsanjani, Sony Wibisono, Chandra Irwanadi
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
